Donald Cameron

Donald Cameron

Visiting address: Solnavägen 9, 17165 Stockholm
Postal address: C5 Cell- och molekylärbiologi, C5 CMB Baranello, 171 77 Stockholm
Part of:

About me

  • My background is in ribosomal DNA (rDNA) transcription, topoisomerase biology
    and cancer therapy. I graduated with a Bachelor of Science (Hons) from the
    University of Melbourne in 2010. After working at the Peter MacCallum Cancer
    Centre as a research assistant for three years, I undertook my PhD studies
    supervised by Professor Hannan and Dr. Gretchen Poortinga spilt between the
    PMCC and the John Curtin School of Medical Research in Canberra. My PhD
    investigated how tumour cells develop resistance to CX-5461, a first-in-class
    inhibitor of rDNA transcription initiation currently in multi-site Phase I/II
    clinical trials. Through this research, I discovered that CX-5461 acts as a
    hyper-targeted Topoisomerase II inhibitor able to cause DNA damage
    specifically at the site of rDNA transcription initiation, suggesting that
    CX-5461 could provide a less genotoxic alternative to commonly used
    chemotherapy agents.

Research

  • I joined Laura Baranello’s group in June 2018 to investigate the
    interaction between two of the most essential proteins for a tumour cell:
    Top2α and c-Myc. I am also researching potential combination therapies using
    topoisomerase inhibitors and chromatin modulators in patient-derived
    xenograft models of cancer. My goal is to better understand the fundamental
    drivers of tumourigenesis thereby enabling us to design drugs to disrupt
    these processes and inhibit tumour growth in a non-invasive way.

Articles

All other publications

News from KI

Events from KI